Project Grant R15HL177762
Award Date
1/15/25
Completion Date
12/31/27
Dollars Obligated
$432K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $392,660 Project Grant under CFDA Program 93.837 - Cardiovascular Diseases Research to the University of Pennsylvania to investigate the role of red blood cells (RBCs) in regulating the immune response during sepsis. The research aims to: 1) establish the subcellular localization of Toll-like Receptor 7 (TLR7) in human RBCs and determine their RNA-sequestration capabilities during sepsis; 2) determine the role of RBC-TLR7 in...
This $265,347 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development and initial validation of a point-of-care device by Functional Fluidics Inc., a minority-owned small business in Detroit, Michigan. The goal is to create a simple, stand-alone, and potentially CLIA-waived diagnostic system to assess red blood cell sickling under hypoxic conditions as an indicator of sickle cell...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $224,070 to Nova Southeastern University to investigate the use of mesenchymal stromal cell-derived exosomes as probes to better understand immune cell dysfunction and mitochondrial function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The key research objectives are to: 1) Examine the effects of exosomes on immune cell...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $637,526 to Duke University to conduct research on the role of sickle red blood cells (RBCs) in activating neutrophils and promoting vaso-occlusion in sickle cell disease (SCD). The key objectives of the research are to: 1) delineate the characteristics of sickle RBCs that contribute to neutrophil activation, 2) examine the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $608,126 to the Regents of the University of Minnesota to develop and validate single-cell biomarkers for predicting clinical outcomes in sickle cell disease (SCD). The research aims to: 1) define the relationship between SCD adverse outcomes and single-cell biochemical/mechanical properties to identify the most promising biomarkers; 2) define the...
This $677,600 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to gain a mechanistic understanding of erythroid progenitor (EP) self-renewal, both in vitro and in vivo. The primary goals are to: Test the hypothesis that the BMI1/RING1B chromatin modulators regulate human self-renewing erythroblast (SRE) self-renewal through epigenetic control of transcription and cholesterol homeostasis. Test the hypothesis that...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $150,220 to Texas Tech University System to study the magnetic properties of red blood cells and monocytes in sickle cell disease (SCD) patients. The goal is to investigate how the magnetic signature and hemoglobin content of these cells can be used to predict the development of vaso-occlusive crises, the major...
This Project Grant award of $444,125 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research at Duke University to investigate the impact of red cell exchange (RCE) procedures on neutrophil function in sickle cell disease (SCD) patients. The research aims to determine if RCE, which replaces abnormal sickle hemoglobin red blood cells with normal hemoglobin cells, can modulate neutrophil reactivity and function,...
This Project Grant award of $1,276,908 from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research, will support advanced research by Bloodworks, a non-profit organization based in Seattle, Washington. The research aims to increase understanding of the mechanisms of disease in von Willebrand disease and sickle cell disease, which both involve the von Willebrand factor. Key focus areas include investigating the impact of VWF cleavage fragments...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $465,000 in funding to Bloodworks, a non-profit organization based in Seattle, WA. The award supports research into the mechanisms by which chronic inflammation disrupts hemostatic function in sickle cell disease (SCD). Specifically, the project aims to investigate how TNF-driven inflammation in SCD blocks autophagy and mitophagy in...